MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merck & Co. is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock is technically constructive, analyst sentiment is broadly positive, and options sentiment is bullish. Despite the recent Alzheimer’s program setback, the market has not broken the uptrend, and MRK remains a reasonable long-term accumulation candidate at current levels. Given the user’s impatience and preference not to wait for a perfect entry, this is a buy now rather than a hold.
MRK is in a bullish technical setup. The MACD histogram is positive and expanding, indicating strengthening momentum. The moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), which supports an ongoing uptrend. RSI_6 at 70.45 is near overbought but still not a clear reversal signal. Price at 129.8 is above the pivot (121.836) and near R1 (128.987), showing strong price action after the recent move. The setup suggests trend continuation is still intact, with upside potential toward 133.405 (R2).
["BofA raised its price target to $141 and kept a Buy rating.", "Scotiabank raised its price target to $155 and kept an Outperform rating.", "CICC initiated coverage with an Outperform rating and $138 target.", "JPMorgan remains Overweight and sees favorable risk/reward into 2026 and 2027 data readouts.", "Bullish technical momentum with expanding MACD and aligned moving averages.", "Options activity shows bullish call demand.", "Recent price action is holding above key support and near resistance breakout territory."]
["Merck halted MK-1167 in Alzheimer\u2019s after poor mid-stage results, which pressured sentiment.", "Citi is still Neutral and wants more clinical catalysts and business development.", "Insiders are selling, with selling activity increasing sharply over the last month.", "The stock is near overbought RSI territory after a recent strong move.", "Hedge funds are neutral, with no strong accumulation trend over the last quarter."]
No usable latest-quarter financial snapshot was provided because the financial snapshot field returned an error. The only available financial context is that analysts referenced Merck's Q1 report as solid, with the midpoint of guidance raised and the topline beat helped by timing of Keytruda U.S. purchases. That indicates the latest quarter season was solid, with underlying revenue support and stable guidance trends, but there is not enough detailed financial data here to assess full growth metrics.
Analyst sentiment has improved recently. Several firms raised price targets in late June and early July: BofA to $141 with Buy, Scotiabank to $155 with Outperform, CICC initiated with Outperform at $138, and UBS/JPMorgan remain constructive. One notable offset is Citi’s Neutral rating with a $125 target, reflecting caution until more clinical catalysts emerge. Overall Wall Street is mostly bullish, with the main pro being favorable valuation/risk-reward and pipeline upside, and the main con being dependence on future clinical execution and event-driven catalysts.
